Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) EBITDA (2020 - 2025)

Janux Therapeutics (JANX) has disclosed EBITDA for 6 consecutive years, with -$32.2 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA fell 24.37% to -$32.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$111.5 million, a 65.15% decrease, with the full-year FY2025 number at -$111.5 million, down 65.15% from a year prior.
  • EBITDA was -$32.2 million for Q4 2025 at Janux Therapeutics, down from -$23.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$2.3 million in Q1 2021 to a low of -$33.9 million in Q2 2025.
  • A 5-year average of -$16.6 million and a median of -$16.3 million in 2023 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: plummeted 756.61% in 2021, then surged 60.45% in 2024.
  • Janux Therapeutics' EBITDA stood at -$13.7 million in 2021, then dropped by 11.77% to -$15.3 million in 2022, then soared by 35.27% to -$9.9 million in 2023, then tumbled by 160.98% to -$25.9 million in 2024, then fell by 24.37% to -$32.2 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's EBITDA are -$32.2 million (Q4 2025), -$23.5 million (Q3 2025), and -$33.9 million (Q2 2025).